Wellington Management Group LLP Purchases New Position in ANI Pharmaceuticals, Inc. $ANIP

Wellington Management Group LLP purchased a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 8,206 shares of the specialty pharmaceutical company’s stock, valued at approximately $549,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Millennium Management LLC grew its position in shares of ANI Pharmaceuticals by 89.3% during the 4th quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company’s stock worth $55,437,000 after purchasing an additional 473,097 shares in the last quarter. Aberdeen Group plc grew its position in shares of ANI Pharmaceuticals by 76.1% during the 1st quarter. Aberdeen Group plc now owns 419,099 shares of the specialty pharmaceutical company’s stock worth $28,059,000 after purchasing an additional 181,134 shares in the last quarter. Deep Track Capital LP grew its position in shares of ANI Pharmaceuticals by 28.6% during the 4th quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company’s stock worth $35,879,000 after purchasing an additional 144,214 shares in the last quarter. Global Alpha Capital Management Ltd. grew its position in shares of ANI Pharmaceuticals by 17.8% during the 1st quarter. Global Alpha Capital Management Ltd. now owns 735,590 shares of the specialty pharmaceutical company’s stock worth $49,248,000 after purchasing an additional 111,040 shares in the last quarter. Finally, GAMMA Investing LLC grew its position in shares of ANI Pharmaceuticals by 17,558.4% during the 1st quarter. GAMMA Investing LLC now owns 95,002 shares of the specialty pharmaceutical company’s stock worth $6,360,000 after purchasing an additional 94,464 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on ANIP shares. Piper Sandler restated an “overweight” rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Guggenheim restated a “buy” rating and set a $86.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, May 12th. Zacks Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 21st. HC Wainwright restated a “buy” rating and set a $93.00 target price (up previously from $84.00) on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Finally, Truist Financial increased their target price on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a “hold” rating in a research report on Monday, August 11th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $84.75.

ANI Pharmaceuticals Stock Performance

Shares of ANI Pharmaceuticals stock opened at $93.50 on Tuesday. The company has a 50 day moving average of $73.93 and a 200-day moving average of $67.36. ANI Pharmaceuticals, Inc. has a 1-year low of $52.50 and a 1-year high of $93.72. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39. The company has a market cap of $2.03 billion, a PE ratio of -121.43 and a beta of 0.63.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.38. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The company had revenue of $211.37 million during the quarter, compared to the consensus estimate of $187.18 million. During the same quarter in the prior year, the firm posted $1.02 EPS. The firm’s quarterly revenue was up 53.2% on a year-over-year basis. As a group, equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Insider Activity at ANI Pharmaceuticals

In related news, COO Muthusamy Shanmugam sold 52,988 shares of the stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $90.44, for a total value of $4,792,234.72. Following the completion of the transaction, the chief operating officer owned 431,920 shares of the company’s stock, valued at $39,062,844.80. This represents a 10.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Matthew J. Leonard sold 2,528 shares of the stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $90.62, for a total transaction of $229,087.36. Following the completion of the transaction, the director directly owned 6,864 shares of the company’s stock, valued at approximately $622,015.68. The trade was a 26.92% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 405,538 shares of company stock worth $35,690,131 in the last 90 days. Corporate insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.